What you'll learn
- Describe the optimal treatment approach to patients with oligometastatic cancers of the genitourinary tract
- Explain the role of immunotherapy in the management of bladder and renal cancer
- Determine how to incorporate genomic classifiers, multiple parametric MRI, and clinical parameters into selecting optimal patients with prostate cancer for active surveillance or other definitive management approaches
- Apply Level 1 evidence on the use of novel treatment and surveillance options for patients with prostate, renal, bladder, or testicular cancer
- Apply novel minimally invasive treatments for GU malignancies including prostate, bladder and kidney cancer
- Use multiparametric MRI, fusion biopsy and novel markers in men at risk for prostate cancer
This is an accredited, livestreamed course offered by Brigham and Women's Hospital. This course is targeted to primary care physicians, specialty physicians, nurses, nurse practitioners, physician assistants, resident and fellow. This course may also be of interest to physicians who practice in radiation oncology, urology, radiology, pathology, oncology, and hematology, nuclear medicine, medical genetics and genomics, internal medicine,hospice and palliative medicine, healthcare education and leadership, geriatrics, and family medicine.
Select the Take Course button to view additional information on the course registration page.
*Register before Aril 12 to receive the discounted price.
Harvard Medical School
You may also like
- Learn about the latest evidenced-based medicine and guidelines for diagnosing, treating, and managing the care of patients with...